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Detection and Imaging of Cardiac
Allograft Vasculopathy
Ari Pollack, MD,* Tamim Nazif, MD,*† Donna Mancini, MD,*‡ Giora Weisz, MD*†
New York, New York
Cardiac allograft vasculopathy (CAV) is an important cause of morbidity and mortality among cardiac
transplant recipients. CAV occurs in approximately 30% of patients by 5 years and 50% by 10 years, and is
a major cause of graft loss and death. Early detection of CAV is important because it may allow alterations
inmedical therapybeforeprogression to the stage that revascularization is required. This has led to routine
screening for CAV in transplant recipients, traditionally by invasive coronary angiography (ICA). Recent
advances in imaging technology, specifically intravascular ultrasound, now also permit detection of
subangiographic CAV. Noninvasive stress testing andmultislice coronary computed tomography angiog-
raphy have been investigated as noninvasive alternatives to routine ICA. However, currently available
noninvasive tests remain limitedwith respect to their sensitivity and specificity for CAV. Given themultiple
available diagnostic modalities, no consensus definition for the classification of CAV has been widely
accepted, although new guidelines that rely heavily on ICA have recently been published by the Interna-
tional Society of Heart and Lung Transplantation. This review summarizes imaging modalities that are
utilized in the diagnosis and surveillance of CAV and explores newer imaging techniques that may play a
future role. (J Am Coll Cardiol Img 2013;6:613–23) © 2013 by the American College of Cardiology
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aredardiac transplantation is the definitive
treatment for end-stage cardiomyop-
athy of any cause. The International
Society for Heart and Lung Trans-
lantation estimates that more than 5,000
eart transplants are performed each year
orldwide (1). In 2010, 2,333 transplants were
one in the United States alone (2). The
edian survival after transplantation has
teadily improved and now exceeds 10 years
1). With improvement in long-term survival,
From the *Department of Medicine, New York–Presbyterian Hosp
University, New York, New York; †Center for Interventional V
Columbia University Medical Center, Columbia University, New Y
Failure and Cardiac Transplant, New York–Presbyterian Hospit
University, New York, New York. Dr. Weisz is a consultant to Infr
no relationships relevant to the contents of this paper to disclose.Manuscript received June 11, 2012; revised manuscript received Marchardiac allograft vasculopathy (CAV) has be-
ome an increasingly important cause of morbid-
ty and mortality among transplant recipients (3).
he incidence of CAV is approximately 8% at 1
ear, 30% at 5 years, and 50% at 10 years, and it
s a major cause of graft loss and death after the
rst year (1).
CAV is an accelerated fibroproliferative pro-
ess that affects the coronary arteries of cardiac
llografts (4). Risk factors include the number
f HLA-DR mismatches; older donor age and
Columbia University Medical Center, Columbia
lar Therapy, New York–Presbyterian Hospital,
New York; and the ‡Center for Advanced Heart
olumbia University Medical Center, Columbia
ex. All other authors have reported that they have18, 2013, accepted March 21, 2013.
i
p
q
a
p
v
C
a
D
e
I
a
I
M
M
i
N
O
t
PPV positive predictive va
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 6 , N O . 5 , 2 0 1 3
M A Y 2 0 1 3 : 6 1 3 – 2 3
Pollack et al.
Imaging of Cardiac Allograft Vasculopathy
614donor history of hypertension; and younger recipi-
ent age, and presence of recipient diabetes and
obesity (1,5). The pathophysiology of CAV in-
volves immunologic and nonimmunologic factors
that cause inflammation with persistent vascular
injury and endothelial dysfunction (6–9). Histolog-
cally, there is subendothelial accumulation of lym-
hocytes (primarily T cells), myointimal proliferation
of smooth muscles cells, development of lipid-laden
foam cells, and perivascular fibrosis (10–12). Con-
centric intimal hyperplasia leads to progressive lu-
minal compromise resulting in a diffuse obliterative
process of the intramural and epicardial coronary
arteries (Fig. 1) (13–17). Eventually, decreased
coronary blood flow and reduced vasodilatory ca-
pacity lead to ischemia and ventricular dysfunction
(18,19). By contrast, traditional athero-
sclerotic coronary artery disease (CAD)
typically evolves over a longer time period,
is focal and noncircumferential, and in-
volves more calcium deposition during the
late stages (Fig. 2) (4). Although CAV
typically manifests as diffuse luminal nar-
rowing, lesions can also be focal and ec-
centric with an appearance similar to typ-
ical CAD (16,17,20). Since CAV can
occur in combination with CAD, which
may be present in allografts due to either
de novo atherosclerosis or pre-existing do-
nor atherosclerosis (20–22), distinguish-
ing between these processes may be chal-
lenging. It remains to be determined
whether this distinction will be important
from a clinical standpoint.
The early detection of CAV is critically
important because it may allow alterations
of medical therapy before progression to
the stage that revascularization is required. There is
evidence that modification of immunosuppressive
regimens may delay CAV progression or even cause
regression (23–26). However, early diagnosis re-
mains challenging due to absent or atypical symp-
tomatology related to allograft denervation (27–31).
Although cardiac reinnervation may occur in 10%
to 30% of cases, typical angina remains uncommon
(27,31). In 1 study of 29 myocardial infarctions
identified in explanted allografts at autopsy or
retransplantation, a history of chest or arm pain was
reported in only 12% of cases (30). In fact, the
initial manifestations of CAV can be allograft
dysfunction, silent myocardial infarction, or sudden
death (29). This has led to routine screening of
se
hy
und
ness
alue
lueheart transplant recipients for CAV, most oftenwith invasive coronary angiography (ICA). Al-
though CAV typically progresses gradually, it can
also evolve rapidly and unpredictably (19,32–34).
Rapid progression of CAV, especially in the first 5
years after transplantation, is a powerful predictor of
the development of advanced disease, myocardial
infarction, and mortality (35–37).
CAV was initially diagnosed by histopathologic
examination, but advances in management have
prolonged graft and patient survival, allowing for
angiographic diagnosis. Advances in imaging tech-
nology, specifically intravascular ultrasound
(IVUS), now also permit detection of subangio-
graphic CAV. Noninvasive stress testing, particu-
larly with dobutamine stress echocardiography
(DSE), has been investigated as a way to decrease
the need for ICA. Recently, multislice coronary
computed tomography angiography (CTA) has also
been investigated as a noninvasive alternative to
ICA. However, these noninvasive tests remain lim-
ited with respect to their sensitivity and specificity
for the diagnosis of CAV. In 2010, the Interna-
tional Society for Heart and Lung Transplantation
published a new consensus document for the clas-
sification of CAV based primarily on angiography
(3). The purpose of this review is to describe the
imaging modalities that are utilized in the diagnosis
and prognostic surveillance of CAV.
Diagnosis of CAV
Noninvasive stress testing. Due to the high fre-
uency of baseline electrocardiogram abnormalities
nd the reduced exercise capacity of cardiac trans-
lant recipients, the specificity of exercise stress
Figure 1. Histology of CAV
Marked concentric intimal hyperplasia and proliferation associ-
ated with cardiac allograft vasculopathy (CAV) along with a pre-
dominance of lymphocytes and foam cells. Image courtesy ofA B B R E V I A T I O N S
A N D A C R O N YM S
CAD coronary artery disea
CAV cardiac allograft
asculopathy
TA computed tomograp
ngiography
SE dobutamine stress
chocardiography
CA invasive coronary
ngiography
VUS intravascular ultraso
ITmaximal intimal thick
PImyocardial perfusion
maging
PV negative predictive v
CT optical coherence
omographyDr. Charles Marboe, Columbia University Medical Center.
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615electrocardiography alone for detection of CAV is
poor and adjunctive imaging is generally required
(38). Echocardiography and radionuclide imaging
have been used to improve both sensitivity and
specificity.
Multiple studies have compared the performance
of DSE and ICA with or without IVUS for detecting
the presence and severity of CAV (39–44). Studies
have demonstrated that regional myocardial dysfunc-
tion as assessed by DSE correlates well with IVUS
evidence of moderate to severe intimal hyperplasia in
cardiac allografts (42,43). In comparison to ICA, the
sensitivity, specificity, positive predictive value (PPV),
Figure 2. Histology of Native Coronary Atherosclerosis
An example of a primarily ﬁbrotic plaque with a paucity of lym-
phocytes. Notice the eccentric proliferation of the intima, in con-
trast to the concentric intimal hyperplasia commonly seen in
cardiac allograft vasculopathy (CAV). Image courtesy of Dr.
Charles Marboe, Columbia University Medical Center.
Table 1. Stress Tests in the Evaluation of CAV
First Author (Ref. #) Modality
Patients
(N)
Derumeaux et al. (39) DSE 37
Akosah et al. (40) DSE 41
Spes et al. (42) DSE 98
Spes et al. (43) DSE 46
Derumeaux et al. (44) DSE 41
Ciliberto et al. (49) Dipyridamole technetium-99m
sestamibi SPECT
78
Ciliberto et al. (49) Dipyridamole technetium-99m
sestamibi SPECT
78
Wu et al. (50) Dobutamine thallium SPECT 47
Elhendy et al. (51) Dobutamine technetium-99m
tetrofosmin SPECT
50
CAV  cardiac allograft vasculopathy; DSE  dobutamine stress echocardiogra
SPECT  single-photon emission computed tomography; NPV  negative predictivand negative predictive value (NPV) of DSE for the
diagnosis of CAV range from 65% to 95%, 55% to
95%, 69% to 92%, and 71% to 92%, respectively
(Table 1) (39,41,44). The relatively strong NPV of
SE compared with ICA has led some centers to use
SE to increase the interval between invasive screen-
ng tests in the appropriate clinical setting. With the
ddition of IVUS to ICA, the sensitivity, specificity,
PV, and NPV of DSE for CAV range from 72% to
9%, 83% to 88%, 88% to 92%, and 62% to 71%,
espectively (Table 1) (42,43). The lower sensitivity
nd NPV of DSE compared with IVUS is most likely
reflection of the superior sensitivity of IVUS relative
o ICA for detection of CAV (see the following text).
Assessment of coronary flow reserve with dobut-
mine stress contrast-enhanced transthoracic echo-
ardiography is in the preliminary stages of inves-
igation as a screening test for CAV (45–47). In 1
tudy, this modality was compared with ICA in 35
symptomatic transplant recipients and had a sen-
itivity of 70% and specificity of 96% for the
resence of a focal stenosis 50% (47). However,
bnormalities were detected in only 1 of the 5
atients with multivessel disease. This method re-
uires high image quality, which may be difficult to
chieve in some cardiac transplant recipients due to
uboptimal acoustic windows.
Stress radionuclide myocardial perfusion imaging
MPI), with either exercise or pharmacological
tress modalities, has also been evaluated for the
etection of CAV (48–51). The sensitivity of ex-
rcise stress MPI for detection of traditional CAD
as been shown to be decreased in patients with
mparator CAV Diagnosis
Sensitivity
(%)
Spe
A Angiographic focal stenosis 50% 65
A Angiographic luminal irregularities
or diffuse disease
95
A or IVUS Angiographic luminal irregularities
or IVUS MIT 0.3 mm
72
US MIT 0.3 mm 79
A Angiographic luminal irregularities
or diffuse disease
86
A Angiographic focal stenosis 50%
or diffuse disease
92
A Angiographic luminal narrowing
(any CAV)
56
A Angiographic focal stenosis 50%
or diffuse disease
89
A Angiographic focal stenosis 50% 90
ICA  invasive coronary angiography; IVUS  intravascular ultrasound; MIT  mCo
ciﬁcity
(%)
PPV
(%)
NPV
(%)
IC 95 92 76
IC 55 69 92
IC 88 92 62
IV 83 88 71
IC 91 86 91
IC 86 55 98
IC 89 70 81
IC 71 42 96
IC 55 75 79
phy; aximal intimal thickness;
e value; PPV  positive predictive value.
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616submaximal exercise tolerance (52–54). The limited
sensitivity of this modality for detection of CAV,
ranging from 60% to 77% in available studies, may
therefore be related to the known impairment of
exercise tolerance in cardiac transplant recipients
(48,55–57). The use of pharmacological stress
agents has been demonstrated to improve the sen-
sitivity and NPV, but the specificity and PPV
remain limited (Table 1). Furthermore, the diag-
nostic performance of stress MPI has been shown
to be even poorer for the detection of nonobstruc-
tive (50% stenosis) CAD (49).
Overall, noninvasive stress testing modalities,
specifically DSE and pharmacological MPI, offer
reasonable sensitivity and NPV for the detection of
significant obstructive CAV. However, these mo-
dalities have limited specificity and PPV for CAV,
and remain insufficiently sensitive to reliably detect
early-stage or limited disease. Thus, invasive tech-
niques remain the standard of care for the diagnosis
and surveillance of CAV.
Coronary angiography. Invasive coronary angiogra-
phy is the screening and surveillance test of choice
for CAV at most cardiac transplant centers and is
typically performed on a routine periodic basis (3).
The prevalence of CAV detected by ICA is approx-
imately 10% to 20% at 1 year and 35% to 50% at 5
years (9,34,58–60). The angiographic diagnosis of
CAV has prognostic significance for graft survival,
patient survival, and adverse cardiac events. How-
ever, concern remains regarding the sensitivity of
coronary angiography for CAV when compared
with IVUS and histopathologic studies (3,61–64).
Coronary angiography also exposes patients to the
risks of an invasive procedure and necessitates the
use of iodinated contrast, which may pose an
increased risk of kidney injury in cardiac transplant
recipients, among whom chronic kidney disease is a
common comorbidity (65).
Multiple definitions and classification schemes
for the angiographic diagnosis of CAV exist in the
literature, with stenosis thresholds ranging from
30% to 70% (9,62,66). Early work by Gao and
colleagues (66) attempted to standardize the de-
scription of CAV lesion type and led to a classifi-
cation system that was widely adopted. However,
the classification system subsequently failed to dem-
onstrate prognostic significance, leading to the de-
velopment of newer classification schemes (3). New
guidelines for the classification of CAV were pub-
lished in 2010 by the International Society of Heart
and Lung Transplantation (3). They integrate cor-onary angiographic findings with assessment of
graft function and hemodynamics (Table 2).
Although ICA remains the standard of care,
studies have raised concern regarding its limited
sensitivity for the detection of early-stage CAV
(62,67–69). ICA assesses the vessel lumen, but does
not permit evaluation of the arterial wall. Although
traditional CAD typically causes focal, eccentric
narrowing of the vessel lumen, CAV is more often
a diffuse process that initially manifests as intimal
thickening and evolves into concentric, longitudinal
lesions (Fig. 3) (13–16,70). This process may be
difficult to detect by luminal assessment alone,
particularly in the early stages. In a histopathologic
study of 10 explanted allografts within 2 months of
a normal ICA, 75% were found to have significant
intimal hyperplasia, indicative of CAV (61). Studies
comparing ICA with IVUS have demonstrated
sensitivity, specificity, PPV, and NPV for the diag-
Table 2. ISHLT Recommended Nomenclature For CAV
Classiﬁcation Severity Deﬁnition
ISHLT CAV0 Not
signiﬁcant
No detectable angiographic
lesions
ISHLT CAV1 Mild Angiographic LM 50%, or
primary vessel with maximum
lesion of 70%, or any
branch stenosis of 70%
(including diffuse narrowing)
without allograft dysfunction
ISHLT CAV2 Moderate Angiographic LM 50%; a single
primary vessel 70%, or
isolated branch stenosis of
70% in branches of 2
systems, without allograft
dysfunction
ISHLT CAV3 Severe Angiographic LM 50%, or 2 or
more primary vessels 70%
stenosis, or isolated branch
stenosis 70% in all 3
systems; or ISHLT CAV1 or
CAV2 with allograft
dysfunction (deﬁned as LVEF
45%, usually in the presence
of regional wall motion
abnormalities) or evidence of
signiﬁcant restrictive
physiology
A “primary vessel” denotes the proximal and middle 33% of the left anterior
descending artery, the left circumﬂex, the ramus, and the dominant or
codominant right coronary artery with the posterior descending and postero-
lateral branches. A “secondary branch vessel” includes the distal 33% of the
primary vessels or any segment within a large septal perforator, diagonals,
and obtuse marginal branches or any portion of a nondominant right
coronary artery. Restrictive cardiac allograft physiology is deﬁned as symp-
tomatic heart failure with echocardiographic E to A velocity ratio of 2 (1.5
in children), shortened isovolumetric relaxation time (60 ms), shortened
deceleration time (150 ms), or restrictive hemodynamic values (right atrial
pressure 12 mm Hg, pulmonary capillary wedge pressure 25 mm Hg,
cardiac index 2 l/min/m2). Adapted from the 2010 ISHLT consensus
statement for recommended nomenclature of CAV (3).
CAV cardiac allograft vasculopathy; ISHLT International Society of Heart
and Lung Transplantation; LM  left main coronary artery; LVEF  left
ventricular ejection fraction.nosis of CAV that range from 43% to 44%, 81% to
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61795%, 90% to 92%, and 27% to 57%, respectively
(63,71). The limited sensitivity and NPV of ICA
relative to IVUS has led to increasing interest in the
use of intravascular imaging to facilitate the early
diagnosis of CAV.
Intravascular imaging. The initial manifestations of
CAV are confined to the arterial wall, so the ability
of intravascular ultrasound to define the intimal and
medial layers of the coronary arteries makes it
particularly useful in the assessment of early-stage
disease (Fig. 4). On IVUS assessment, half of
transplant recipients with angiographically normal
coronary arteries later than 1 year after transplan-
tation have moderate or severe intimal thickening of
the left anterior descending coronary artery (69).
Due to its superior sensitivity, IVUS is now being
used by some centers as the diagnostic test of choice
for detection of early CAV.
The use of IVUS has also led to important
advances in the understanding of the natural his-
tory, distribution, and morphology of CAV
(16,17,20–22,72,73). Serial IVUS imaging has
shown that the dynamic process of coronary artery
remodeling begins within the first year after trans-
plantation (74). Initially, there is thickening of the
coronary intima, which occurs in more than 80% of
patients within 1 year after transplantation
(16,17,63). In addition, affected arteries develop an
early expansion of the external elastic membrane
with preservation of luminal area (75–77). Changes
in the external elastic membrane tend to occur in a
biphasic pattern, with early expansion followed by
late, concentric remodeling and reductions in lumi-
nal area (77).
Radiofrequency IVUS has been investigated in
traditional atherosclerotic CAD to delineate the
components of coronary lesions and classify
plaque based on its composition (78 – 80). In
transplant recipients, it has demonstrated that
lesions in the early post-transplant period tend to
be focal, noncircumferential, and composed
mainly of fibrous and fibrofatty tissue. The pres-
ence of lesions with a necrotic core early after
transplantation is associated with older donors,
male recipients, and diabetes and may represent
traditional atherosclerosis rather than CAV
(22,72). Fibrous and fibrofatty plaque remain the
predominant lesions, regardless of time from
transplantation, and can be representative of
either CAV or traditional atherosclerosis
(11,13,22). However, calcified lesions with ne-
crotic cores, markers of traditional atherosclerotic
disease, begin to increase within 2 years oftransplantation and become more prevalent with
time (72). Inflammatory plaques (composed of
30% necrotic core with dense calcification) are
associated with a higher rejection score as well as
subsequent progression of CAV when compared
with noninflammatory plaques (26). The clinical
use and interpretation of radiofrequency IVUS
must be undertaken with caution since it has not
been well validated by histopathologic studies of
cardiac allografts.
Despite its superior sensitivity and the demon-
strated prognostic value of intimal thickening,
IVUS has not been widely adopted as a routine
screening test for CAV due to several limitations.
Intimal proliferation assessed by IVUS does not
necessarily correlate with small-artery disease by
histologic or immunohistochemical analysis
(3,81). In addition, the size of currently available
IVUS catheters makes direct imaging of the
distal, small-caliber vasculature technically diffi-
cult (82). Furthermore, multivessel imaging is
necessary to optimize the sensitivity of IVUS for
detection of CAV. In 1 study, the prevalence of
Figure 3. Distinct Manifestations of CAV
Coronary angiography demonstrating distinct manifestations of car
allograft vasculopathy. (A and B) The classical angiographic appear
cardiac allograft vasculopathy (CAV) with multiple sequential lesion
fuse narrowing of the coronary arteries, and prominent pruning of
tal vasculature. (C and D) CAV can also appear similar to typical
atherosclerotic coronary artery disease in a native heart. A focal, pr
left anterior descending (LAD) coronary artery lesion.diac
ance of
s, dif-
the dis-
oximalCAV in patients with 1, 2, or 3 vessels imaged
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618was 27%, 41%, and 58% at 1 year and 29%, 55%,
and 74% at 3 years (83). The complication rate of
multivessel IVUS imaging has been shown to be
1.6% (84). Finally, increased cost and lack of
expertise may limit the widespread availability of
IVUS. For these reasons, the routine use of IVUS
for the detection and surveillance of CAV is not
currently recommended.
Since the pathophysiology of CAV and conven-
tional atherosclerosis are distinct, an imaging mo-
dality with the capability for near-histologic char-
acterization may be potentially useful from a
diagnostic, prognostic, and therapeutic perspective.
Optical coherence tomography (OCT) is a high-
resolution (10 m), intravascular, light-based im-
aging modality that measures the intensity of re-
flected light waves and converts these echoes into a
high-resolution tomographic image (85). OCT has
been used to visualize and characterize coronary
atherosclerotic plaque composition, including inti-
mal hyperplasia, delineate between intima and
plaque, resolve thin fibrous caps, image beyond
calcified tissue, and differentiate between fibrous
and lipid-rich plaque (86,87). The potential role of
OCT imaging in cardiac transplant recipients is
currently being studied.
Cardiac computed tomography angiography. Cardiac
computed tomography angiography has the poten-
tial to be a noninvasive alternative to ICA for the
diagnosis of CAV. In addition to the vessel lumen,
coronary CTA also allows some evaluation of the
arterial wall, which could potentially enhance its
sensitivity for CAV. Modern multidetector and
dual-source technology has significantly improved
Figure 4. IVUS Imaging of CAV
Intravascular ultrasound (IVUS) frames of transplant vasculopathy co
proximal LAD, and (C) distal left main (LM) of the same patient afte
characteristics are the diffuse atheromatosis, the concentric, rather
an integration of positive and negative remodeling. CAV  cardiac
vascular Research Foundation.spatial and temporal resolution, allowing adequateevaluation of 81% to 100% of coronary segments
1.5 mm in diameter (88–95).
Several studies have compared the performance
of multidetector (16- or 64-slice) and dual-source
coronary CTA with ICA and/or IVUS for the
diagnosis of CAV (Table 3). The consistently high
NPV of coronary CTA relative to ICA has led to
interest in its use as the primary screening test for
CAV. A potential future benefit of coronary CTA
is the ability to evaluate wall thickening that is not
apparent by ICA. However, with current technol-
ogy, the NPV of coronary CTA as compared with
IVUS remains low, reflecting the superior sensitiv-
ity of IVUS.
Important limitations remain with respect to the
use of coronary CTA in the evaluation of CAV.
Existing studies have limited analysis to coronary
segments 1.5 mm in diameter, and evaluation of
the smaller distal vasculature, where CAV often
manifests, may be inadequate. Chronic kidney dis-
ease is a common comorbidity in cardiac transplant
recipients, and the risk of kidney injury may be
increased with coronary CTA, which typically re-
quires a large contrast load. In fact, the majority of
trials of coronary CTA for CAV have excluded
patients with significant renal insufficiency
(90,91,96–99). The radiation dose with coronary
CTA is also typically higher than with standard
ICA, and this may be of particular concern in
cardiac transplant recipients who require serial ra-
diographic examinations (91,92,97,98). Many of
the limitations of coronary CTA are likely to
improve with ongoing advances in imaging tech-
ponding to (A) middle left anterior descending artery (LAD), (B)
year of heart transplantation. The major morphological plaque
eccentric, disease pattern, the lack of signiﬁcant calciﬁcation, and
graft vasculopathy. Images courtesy of Dr. Elias Sanidas, Cardio-rres
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619prognosis of cardiac transplant recipients followed
by serial coronary CTA.
Prognosis of CAV
Noninvasive stress testing. Multiple studies have
emonstrated the prognostic significant of non-
nvasive stress testing in cardiac transplant recip-
ents. Studies have shown that a normal DSE in
his setting has a NPV ranging from 92% to
00% for subsequent cardiac events (41,42,100).
his strong NPV has led some centers to use
SE to increase the interval between required
CA in appropriate clinical circumstances, par-
icularly when serial angiograms are normal. On
he other hand, studies have demonstrated that
bnormal myocardial perfusion as assessed by
tress MPI is an independent predictor of cardiac
eath in transplant recipients (50,93,101). Fur-
hermore, both abnormal and serially worsening
SE findings have been shown to predict major
ardiac events in transplant recipients (42). Over-
ll, the current literature supports a potential role
or noninvasive stress testing to lengthen the
nterval between required ICA or as a screening
est for CAV in patients with a contraindication
o ICA (i.e., renal failure or contrast allergy).
Coronary angiography. The diagnosis of CAV by
CA has also been shown in multiple studies to
ave prognostic importance in cardiac transplant
ecipients. In 1 study, the lack of significant angio-
raphic CAV was a significant predictor of sur-
ival without adverse cardiac events at 2 years
88). In another study of nearly 6,000 post-
ransplant angiograms, the 5-year rate of death or
Table 3. Coronary Computed Tomographic Angiography for the
First Author (Ref. #) Modality
Patients/
Coronary Segments
Eval
Seg
Sigurdsson et al. (91) MDCT-16 54/791 754
Sigurdsson et al. (91) MDCT-16 13/154 154
Schepis et al. (92) DSCT-64 30/459 441
Schepis et al. (92) DSCT-64 30/114 110
Pichler et al. (96) MDCT-16 60/757 711
Romeo et al. (98) MDCT-16 50/450 432
von Ziegler et al. (99) MDCT-64 26/371 302
Gregory et al. (97) MDCT-64 20/122 119
Values are n/N or n (%). Sensitivity, speciﬁcity, PPV, and NPV are reported as pe
excluding segments with signiﬁcant stenosis by quantitative coronary angiogra
DSCT  slice dual-source computed tomography; MDCT  slice multidetector cometransplantation as a result of CAV was 7%
mong all patients and 50% among patients with
evere CAV (9). Both the overall burden and the
ate of progression of CAV have also been shown
o be prognostically important. In 1 study, pa-
ients with single-vessel vessel disease had sur-
ival of 64% at 1 year and 36% at 2 years, but
atients with triple-vessel CAV had a much
orse prognosis with a survival of only 13% at 2
ears (102). In another study, transplant recipi-
nts with moderate, single-vessel disease who did
ot demonstrate angiographic progression at 1
ear were likely to remain free of lesion progres-
ion and adverse clinical events for up to 6 years
94). However, the approximately 50% of pa-
ients who were found to have progression of
AV at 1 year required higher rates of revascu-
arization and had significantly increased risk of
udden death (58,94). The demonstrated prog-
ostic significance of the presence, burden, and
rogression of CAV as assessed by ICA is one of
he reasons that it remains the current standard of
are for the diagnosis and surveillance of CAV.
Intravascular imaging. The IVUS diagnosis of CAV
resence and progression has also been shown to
redict adverse cardiac events and death in car-
iac transplant recipients (16,36,37,95). In 1
tudy, severe intimal thickening, defined as max-
mal intimal thickness (MIT) 0.5 mm, con-
erred a 7-fold increased risk of major cardiac
vents (35). Rapidly progressive CAV, defined as
n increase of 0.5 mm in MIT at a given coronary
ite within the first year after cardiac transplan-
ation, is a particularly poor prognostic indicator
hat has been associated with subsequent devel-
gnosis of CAV
le
ts Comparator CAV Diagnosis
Sensitivity
(%)
Speci
(%
ICA Angiographic stenosis
50%
86 9
) IVUS* MIT 0.5 mm 96 8
ICA Angiographic stenosis
50%
93 8
IVUS MIT 0.5 mm 85 8
ICA Angiographic stenosis
50%
71 9
ICA Angiographic stenosis
50%
80 9
ICA Angiographic stenosis
50%
88 9
IVUS MIT 0.5 mm 70 9
ment, after excluding non-evaluable segments. *Qualitative assessment only of p
.Dia
uab
men
ﬁcity
)
PPV
(%)
NPV
(%)
(95) 9 81 99
(100 8 80 98
(96) 0 48 98
(97) 4 76 91
(94) 9 91 99
(96) 9 80 99
(81) 7 48 100
(98) 2 89 77
r seg roliferative changes after
phyputed tomography; other abbreviations as in Table 1.
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620opment of severe CAV, myocardial infarction,
graft loss, and mortality (16,36,37). This suggests
that the presence and progression of intimal
proliferation, as assessed by IVUS measurement
of MIT, may be a useful prognostic test.
Proposed diagnostic algorithm. An evidence-based
creening algorithm for CAV can be proposed
ased on the literature detailed in the preceding
ext. Routine periodic screening for CAV is neces-
ary due to absent or atypical symptomatology in
he majority of cardiac transplant recipients. It is
ssential that every patient undergo ICA 1 year
fter cardiac transplantation. An early angiogram
with or without IVUS) 1 month after transplanta-
ion may be considered to establish a baseline
ssessment. Abnormal findings at that time are
nlikely to represent CAV and more likely reflect
onor CAD. After the first annual study, ICA is
ecommended on at least a biennial basis in patients
ithout CAV and on an annual basis in those with
AV. Centers with intravascular imaging expertise
ay also elect to perform IVUS at the time of ICA
o identify early-stage, subangiographic CAV. In
atients who are found to have normal coronaries
n serial ICA, the surveillance interval may be
ncreased, potentially with the use of noninvasive
tress testing, such as DSE. In general, noninvasive
tress testing, specifically DSE and MPI, is insuf-
ciently sensitive to detect early disease, and is
eserved for this purpose or for patients with con-2006;99:801–15. 1411–22.Future Directions
Although ICA remains the standard of care for
the diagnosis and surveillance of CAV, IVUS
studies have demonstrated the potential incre-
mental value of modalities that allow assessment
of the arterial wall in addition to the vessel
lumen. With continued technological advances,
improvement in the ability of coronary CTA to
assess the arterial wall and distal small vessels,
while requiring less contrast and radiation, may
allow it to play an increasing role in this arena.
The development of specific pharmacological
therapy for CAV may also increase the clinical
urgency of developing techniques to detect very
early disease and distinguish lesion types. Given
the high resolution of OCT, it may allow for
earlier diagnosis as well as detailed analysis of
CAV lesion types, Further research will be re-
quired to determine whether novel imaging tech-
niques for CAV will alter the management and
clinical outcomes of cardiac transplant recipients.
Given the limited patient population, researchers
will need to collaborate through multicenter
studies to advance this important and growing
field.
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